Normal-weight obesity and clinical outcomes in nondiabetic chronic kidney disease patients: a cohort study

https://doi.org/10.1093/ajcn/nqy006Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

Background

Normal-weight obesity (NWO), defined by a normal body mass index (BMI) and high body fat percentage, has been shown to be associated with cardiometabolic dysfunction and an increased risk of cardiovascular disease and mortality in the general population. However, little is known about the clinical implications of NWO among patients with chronic kidney disease (CKD).

Objective

The aim of this study was to assess the characteristics and outcomes of nondiabetic CKD patients with NWO.

Design

A total of 178 nondiabetic patients with stages 3–5 CKD were prospectively followed for a median of 4.9 y. The patients were classified into 3 different adiposity phenotypes: nonobese [BMI (in kg/m2) <25 and fat mass percentage (FM%) ≤25% for men or ≤35% for women], NWO (BMI <25 and FM% >25% for men or >35% for women), and preobese-obese (BMI ≥25). FM% was determined using the Body Composition Monitor, a multifrequency bioimpedance spectroscopy device. The outcome was a composite of cardiovascular events or all-cause mortality.

Results

The prevalence of NWO was 28.1% among nondiabetic CKD patients with a normal BMI. NWO patients were older, had lower lean body mass, and had higher plasma interleukin-6 concentrations than nonobese patients. However, homeostatic model assessment for insulin resistance levels did not differ between the 2 groups. NWO patients showed a significant 3-fold higher risk of the composite outcome (HR 2.96, 95% CI: 1.13, 7.77; P < 0.05) than did nonobese patients in the fully adjusted model. Preobese-obese patients were not at increased risk compared to nonobese patients.

Conclusions

NWO was associated with the worst prognosis among the 3 different adiposity phenotypes in nondiabetic CKD patients. Our findings suggest the importance of using direct measures of adiposity for risk assessment in CKD patients who are normal-weight.

This trial was registered at clinicaltrials.gov as NCT03285074.

Key Words

body mass index
body composition
obesity
normal-weight obesity
interleukin 6
inflammation
insulin resistance
cardiovascular event
mortality

Abbreviations

baPWV
brachial-ankle pulse wave velocity
CKD
chronic kidney disease
CV
cardiovascular
CVD
cardiovascular disease
eGFR
estimated glomerular filtration rate
FFM
fat-free mass
FFM%
fat-free mass percentage
FM
fat mass
FM%
fat mass percentage
FTI
fat tissue index
hs-CRP
high-sensitivity C-reactive protein
LTI
lean tissue index
NWO
normal-weight obesity
UPCR
urine protein creatinine ratio.

Cited by (0)

Supported by grants from Research Projects MOST 103-2314-B-005-MY2 and MOST 105-2314-B-014-MY3, the Ministry of Science and Technology, ROC, and the Research Projects TCRD-TPE-106-RT-5 and TCRD-TPE-107-18, Taipei Tzu Chi Hospital, Taiwan.

The sponsors and the funders of the study had no role in the data collection and analysis, interpretation of this work, or the decision to submit this work for publication.

Study ID number: NCT03285074; registered at clinicaltrials.gov.